Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Conduit Pharmaceuticals Inc. - Common Stock (NQ:CDT)

0.6201 -0.1600 (-20.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Conduit Pharmaceuticals Inc. - Common Stock

< Previous 1 2 Next >
Conduit Pharmaceuticals Announces Leadership Changes
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Progresses Phase II of its AI Initiative with Sarborg
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
Approval of composition of matter patent in key jurisdiction underscores the Company’s commitment to maximize future out-licensing value 
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Composition of matter patent approval underscores the Company’s solid-form technology to maximize future value and ability to strengthen and broaden its intellectual property portfolio 
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals to Join Russell 3000® Index
From Conduit Pharmaceuticals
Via GlobeNewswire
A Presidio Property Trust Major Investment To Be Part of Russell 2000®
From Presidio Property Trust, Inc.
Via GlobeNewswire
Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare Conference
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656
Collaboration underscores Conduit’s mission to advance promising treatments by developing assets that have already completed Phase I trials 
From Conduit Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.